The University of Southampton
University of Southampton Institutional Repository

Associations of prescribed ADHD medication in pregnancy with pregnancy-related and offspring outcomes: a systematic review

Associations of prescribed ADHD medication in pregnancy with pregnancy-related and offspring outcomes: a systematic review
Associations of prescribed ADHD medication in pregnancy with pregnancy-related and offspring outcomes: a systematic review

Background: Increasing numbers of reproductive-aged women are using attention-deficit/hyperactivity disorder (ADHD) medications. Findings from studies exploring the safety of these medications during pregnancy are mixed, and it is unclear whether associations reflect causal effects or could be partially or fully explained by other factors that differ between exposed and unexposed offspring. Objectives: The aim of this systematic review was to evaluate the adverse pregnancy-related and offspring outcomes associated with exposure to prescribed ADHD medication during pregnancy with a focus on how studies to date have handled the influence of confounding. Methods: We searched PubMed, Embase, PsycINFO, and Web of Science up to 1 July 2019 without any restrictions on language or date of publication. We included all observational studies (e.g., cohort studies, case–control studies, case–crossover studies, cross-sectional studies, and registry-based studies) with pregnant women of any age or from any setting who were prescribed ADHD medications and evaluated any outcome, including both short- and long-term maternal and offspring outcomes. Two independent authors then used the Newcastle–Ottawa Scale to rate the quality of the included studies. Results: Eight cohort studies that estimated adverse pregnancy-related and offspring outcomes associated with exposure to ADHD medication during pregnancy were included in the qualitative review. The included studies had substantial methodological differences in data sources, type of medications examined, definitions of studied pregnancy-related and offspring outcomes, types of control groups, and confounding adjustment. There was no convincing evidence for teratogenic effects according to the relative risk of pregnancy-related and offspring outcomes, and the observed differences in absolute risks were overall small in magnitude. Adjustment for confounding was inadequate in most studies, and none of the included studies adjusted for ADHD severity in the mothers. Conclusion: The current evidence does not suggest that the use of ADHD medication during pregnancy results in significant adverse consequences for mother or offspring. However, the data are too limited to make an unequivocal recommendation. Therefore, physicians should consider whether the advantages of using ADHD medication outweigh the potential risks for the developing fetus according to each woman’s specific circumstances. Future research should attempt to triangulate research findings based on a combination of different designs that differ in their underlying strengths and limitations and should investigate specific confounding factors, the potential impact of timing of exposure, and potential long-term outcomes in the offspring.

1172-7047
731-747
Lin, Li
368f4fd3-300e-4009-9e24-30a299fa62e1
Sujan, Ayesha C.
086feb91-c814-4fae-8feb-7e8e66d32211
Butwicka, Agnieszka
0278213c-6949-4a7f-a82e-6796977601c7
Chang, Zheng
55f11375-90ea-40ab-ae79-3221ac510c2f
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
Quinn, Patrick
a9a74061-59ec-4556-a1e2-9a2f5811c875
Viktorin, Alexander
271a1dd7-38f0-4bbd-9fc9-07326fe4ccb0
Öberg, Sara
71c25d59-8086-45a8-98f2-fea08230b60b
D’Onofrio, Brian
12c7a1f1-6dd6-433e-916e-863d95df20a8
Larsson, Henrik
ccfd1ee7-19aa-465f-aa3f-c7e18beb50c0
Lin, Li
368f4fd3-300e-4009-9e24-30a299fa62e1
Sujan, Ayesha C.
086feb91-c814-4fae-8feb-7e8e66d32211
Butwicka, Agnieszka
0278213c-6949-4a7f-a82e-6796977601c7
Chang, Zheng
55f11375-90ea-40ab-ae79-3221ac510c2f
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
Quinn, Patrick
a9a74061-59ec-4556-a1e2-9a2f5811c875
Viktorin, Alexander
271a1dd7-38f0-4bbd-9fc9-07326fe4ccb0
Öberg, Sara
71c25d59-8086-45a8-98f2-fea08230b60b
D’Onofrio, Brian
12c7a1f1-6dd6-433e-916e-863d95df20a8
Larsson, Henrik
ccfd1ee7-19aa-465f-aa3f-c7e18beb50c0

Lin, Li, Sujan, Ayesha C., Butwicka, Agnieszka, Chang, Zheng, Cortese, Samuele, Quinn, Patrick, Viktorin, Alexander, Öberg, Sara, D’Onofrio, Brian and Larsson, Henrik (2020) Associations of prescribed ADHD medication in pregnancy with pregnancy-related and offspring outcomes: a systematic review. CNS drugs, 34 (7), 731-747. (doi:10.1007/s40263-020-00728-2).

Record type: Review

Abstract

Background: Increasing numbers of reproductive-aged women are using attention-deficit/hyperactivity disorder (ADHD) medications. Findings from studies exploring the safety of these medications during pregnancy are mixed, and it is unclear whether associations reflect causal effects or could be partially or fully explained by other factors that differ between exposed and unexposed offspring. Objectives: The aim of this systematic review was to evaluate the adverse pregnancy-related and offspring outcomes associated with exposure to prescribed ADHD medication during pregnancy with a focus on how studies to date have handled the influence of confounding. Methods: We searched PubMed, Embase, PsycINFO, and Web of Science up to 1 July 2019 without any restrictions on language or date of publication. We included all observational studies (e.g., cohort studies, case–control studies, case–crossover studies, cross-sectional studies, and registry-based studies) with pregnant women of any age or from any setting who were prescribed ADHD medications and evaluated any outcome, including both short- and long-term maternal and offspring outcomes. Two independent authors then used the Newcastle–Ottawa Scale to rate the quality of the included studies. Results: Eight cohort studies that estimated adverse pregnancy-related and offspring outcomes associated with exposure to ADHD medication during pregnancy were included in the qualitative review. The included studies had substantial methodological differences in data sources, type of medications examined, definitions of studied pregnancy-related and offspring outcomes, types of control groups, and confounding adjustment. There was no convincing evidence for teratogenic effects according to the relative risk of pregnancy-related and offspring outcomes, and the observed differences in absolute risks were overall small in magnitude. Adjustment for confounding was inadequate in most studies, and none of the included studies adjusted for ADHD severity in the mothers. Conclusion: The current evidence does not suggest that the use of ADHD medication during pregnancy results in significant adverse consequences for mother or offspring. However, the data are too limited to make an unequivocal recommendation. Therefore, physicians should consider whether the advantages of using ADHD medication outweigh the potential risks for the developing fetus according to each woman’s specific circumstances. Future research should attempt to triangulate research findings based on a combination of different designs that differ in their underlying strengths and limitations and should investigate specific confounding factors, the potential impact of timing of exposure, and potential long-term outcomes in the offspring.

Text
CLEAN_MAIN_TEXT_RESULTS_ADHD medication in pregnancy_20200317 - Accepted Manuscript
Download (349kB)

More information

Accepted/In Press date: 31 March 2020
e-pub ahead of print date: 24 April 2020
Published date: 1 July 2020
Additional Information: Funding Information: Research reported in this publication was supported by the Swedish Research Council (no. 2018-02599 to Larsson and no. 2018-02679 to D’Onofrio), the Swedish Brain Foundation (Viktorin and no. FO2018-0273 to Larsson) and the National Institute on Drug Abuse of the National Institutes of Health under award number R00DA040727 (Quinn) and R01DA048042 (D’Onofrio, Quinn, Oberg). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: © 2020, Springer Nature Switzerland AG.

Identifiers

Local EPrints ID: 439232
URI: http://eprints.soton.ac.uk/id/eprint/439232
ISSN: 1172-7047
PURE UUID: 4cc084b0-a7cd-45f2-a11d-0f7d3df6c2dd
ORCID for Samuele Cortese: ORCID iD orcid.org/0000-0001-5877-8075

Catalogue record

Date deposited: 07 Apr 2020 16:31
Last modified: 17 Mar 2024 05:29

Export record

Altmetrics

Contributors

Author: Li Lin
Author: Ayesha C. Sujan
Author: Agnieszka Butwicka
Author: Zheng Chang
Author: Samuele Cortese ORCID iD
Author: Patrick Quinn
Author: Alexander Viktorin
Author: Sara Öberg
Author: Brian D’Onofrio
Author: Henrik Larsson

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×